The Massachusetts biotech has remained well-funded despite shying away from venture capital investors and seeking funds from private investors.

Plus news on recent financing activity by Alcresta, Alder Biopharmaceuticals, H.I.G Capital and Supernus Pharmaceuticals.

H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.

In the eyes of one West Coast device VC, Sami Hamade has the perfect resume to be a venture capitalist. He spent over a decade at Guidant creating or funding new start-up ventures, both internally and externally. He's sat on boards, demonstrated market savvy and established connections with all the right venture firms and laboratories in Silicon Valley. Now Hamade is prepared to do the job at Aberdare Ventures, a small but highly regarded venture firm based in San Francisco.